Characterization of rat thrombin-activatable fibrinolysis inhibitor (TAFI) - A comparative study assessing the biological equivalence of rat, murine and human TAFI

Journal of Thrombosis and Haemostasis

Volumn 4, Issue 11, 2006, Pages 2470-2477

  Hillmayer, K ^a   Macovei, A ^a   Pauwels, D ^a   Compernolle, G ^a   Declerck, P J ^a   Gils, Ann ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Clot lysis; Fibrinolysis; Rat; TAFI

Indexed keywords

ARGININE; PLASMIN; RECOMBINANT PROTEIN; THROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBOMODULIN;

ANIMAL CELL; ARTICLE; BIOEQUIVALENCE; BLOOD CLOT LYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; FIBRINOLYSIS; HALF LIFE TIME; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN INDUCTION; RAT; RODENT; SPECIES COMPARISON; TEMPERATURE;

ANIMALS; CARBOXYPEPTIDASE U; ENZYME ACTIVATION; FIBRINOLYSIS; HALF-LIFE; HUMANS; MICE; MODELS, ANIMAL; MODELS, CHEMICAL; RATS; RECOMBINANT PROTEINS; SPECIES SPECIFICITY;

EID: 33750079554     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2006.02224.x     Document Type: Article

References (35)

1. Eaton DL, Malloy BE, Tsai SP, Henzel W, Drayna D. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. J Biol Chem 1991; 266: 21833-8.
2. Hendriks D, Wang W, Scharpe S, Lommaert MP, van-Sande M. Purification and characterization of a new arginine carboxypeptidase in human serum. Biochim Biophys Acta 1990; 1034: 86-92.
3. Bajzar L, Morser J, Nesheim M. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 1996; 271: 16603-8.
4. Wang W, Boffa MB, Bajzar L, Walker JB, Nesheim ME. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 1998; 273: 27176-81.
5. Boffa MB, Bell R, Stevens WK, Nesheim ME. Roles of thermal instability and proteolytic cleavage in regulation of activated thrombin-activable fibrinolysis inhibitor. J Biol Chem 2000; 275: 12868-78.
6. Leurs J, Hendriks D. Carboxypeptidase U (TAFIa): A metallocarboxypeptidase with a distinct role in haemostasis and a possible risk factor for thrombotic disease. Thromb Haemost 2005; 94: 471-87.
7. Zeerleder S, Schroeder V, Hack CE, Kohler HP, Wuillemin WA. TAFI and PAI-1 levels in human sepsis. Thromb Res 2006; 118: 205-12.
8. Zirlik A. TAFI: A promising drug target? Thromb Haemost 2004; 91: 420-2.
9. Levi M, Dorffle-Melly J, Johnson GJ, Drouet L, Badimon L. Usefulness and limitations of animal models of venous thrombosis. Thromb Haemost 2001; 86: 1331-3.
10. Kato T, Akatsu H, Sato T, Matsuo S, Yamamoto T, Campbell W, Hotta N, Okada N, Okada H. Molecular cloning and partial characterization of rat procarboxypeptidase R and carboxypeptidase N. Microbiol Immunol 2000; 44: 719-28.
11. Marx PF, Wagenaar GT, Reijerkerk A, Tiekstra MJ, van-Rossum AG, Gebbink MF, Meijers JC. Characterization of mouse thrombin-activatable fibrinolysis inhibitor. Thromb Haemost 2000; 83: 297-303.
12. Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 1995; 270: 14477-84.
13. Schatteman KA, Goossens FJ, Scharpe SS, Hendriks DF. Activation of plasma procarboxypeptidase U in different mammalian species points to a conserved pathway of inhibition of fibrinolysis. Thromb Haemost 1999; 82: 1718-21.
14. Muto Y, Suzuki K, Sato E, Ishii H. Carboxypeptidase B inhibitors reduce tissue factor-induced renal microthrombi in rats. Eur J Pharmacol 2003; 461: 181-9.
15. Suzuki K, Muto Y, Fushihara K, Kanemoto K, Iida H, Sato E, Kikuchi C, Matsushima T, Kato E, Nomoto M, Yoshioka S, Ishii H. Enhancement of fibrinolysis by EF6265 [(S)-7-amino-2- [(R)-2-methyl-1-(3-phenylpropanoy lamino)propyl]hydroxyphosphinoyl] methyl]heptanoic acid], a specific inhibitor of plasma carboxypeptidase B. J Pharmacol Exp Ther 2004; 309: 607-15.
16. Klement P, Liao P, Bajzar L. A novel approach to arterial thrombolysis. Blood 1999; 94: 2735-43.
17. Bjorkman JA, Abrahamsson TI, Nerme VK, Mattsson CJ. Inhibition of carboxypeptidase U (TAFIa) activity improves rt-PA induced thrombolysis in a dog model of coronary artery thrombosis. Thromb Res 2005; 116: 519-24.
18. Wang X, Smith PL, Hsu MY, Ogletree ML, Schumacher WA. Murine model of ferric chloride-induced vena cava thrombosis: Evidence for effect of potato carboxypeptidase inhibitor. J Thromb Haemost 2006; 4: 403-10.
19. Hashimoto M, Oiwa K, Matsuo O, Ueshima S, Okada K, Okada Y, Okamoto S, Giddings JC, Yamamoto J. Suppression of argatroban-induced endogenous thrombolysis by PKSI-527, and antibodies to TPA and UPA, evaluated in a rat arterial thrombolysis model. Thromb Haemost 2003; 89: 820-5.
20. Wu C, Dong N, da Cunha V, Martin-McNulty B, Tran K, Nagashima M, Wu Q, Morser J, Wang Y-X. Activated thrombin-activatable fibrinolysis inhibitor attenuates spontaneous fibrinolysis of batroxobin-induced fibrin deposition in rat lungs. Thromb Haemost 2003; 90: 414-21.
21. Peternel L, Stegnar M, Drevensek G, Budihna MV, Bozic M, Zega Q, Stalc A, Cerne M, Urleb U. Antithrombotic potential of new direct thrombin inhibitors built on the azaphenylalanine scaffold in two rat venous thrombosis models. Thromb Haemost 2005; 93: 437-42.
22. Nazareth RA, Tomaz LS, Ortiz-Costa S, Atella GC, Ribeiro JMC, Franscischetti IMB, Monteiro RQ. Antithrombotic properties of Ixolaris, a potent inhibitor of the extrinsic pathway of the coagulation cascade. Thromb Haemost 2006; 96: 7-13.
23. Gils A, Alessi MC, Brouwers E, Peeters M, Marx P, Leurs J, Bouma B, Hendriks D, Juhan-Vague I, Declerck PJ. Development of a genotype 325-specific proCPU/TAFI ELISA. Arterioscler Thromb Vasc Biol 2003; 23: 1122-7.
24. Gils A, Ceresa E, Macovei AM, Marx PF, Peeters M, Compernolle G, Declerck PJ. Modulation of TAFI function through different pathways - implications for the development of TAFI inhibitors. J Thromb Haemost 2005; 3: 2745-53.
25. Mosnier LO, von-dem-Borne PA, Meijers JC, Bouma BN. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost 1998; 80: 829-35.
26. Leurs J, Wissing BM, Nerme V, Schatteman K, Bjorquist P, Hendriks D. Different mechanisms contribute to the biphasic pattern of carboxypeptidase U (TAFIa) generation during in vitro clot lysis in human plasma. Thromb Haemost 2003; 89: 264-71.
27. Guimaraes AH, Barrett-Bergshoeff MM, Gils A, Declerck PJ, Rijken DC. Migration of the activation peptide of thrombin-activatable fibrinolysis inhibitor (TAFI) during SDS-polyacrylamide gel electrophoresis. J Thromb Haemost 2004; 2: 780-4.
28. Marx PF, Dawson PE, Bouma BN, Meijers JC. Plasmin-mediated activation and inactivation of thrombin-activatable fibrinolysis inhibitor. Biochemistry 2002; 41: 6688-96.
29. Marx PF, Hackeng TM, Dawson PE, Griffin JH, Meijers JC, Bouma BN. Inactivation of active thrombin-activable fibrinolysis inhibitor takes place by a process that involves conformational instability rather than proteolytic cleavage. J Biol Chem 2000; 275: 12410-5.
30. Schneider M, Boffa MB, Stewart R, Raham M, Koschinsky M, Nesheim M. Two naturally occurring variants of TAFI (Thr-325 and Ile-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme. J Biol Chem 2002; 277: 1021-30.
31. Leurs J, Nerme V, Sim Y, Hendriks D. Carboxypeptidase U (TAFIa) prevents lysis from proceeding into the propagation phase through a threshold-dependent mechanism. J Thromb Haemost 2004; 2: 416-23.
32. Walker JB, Bajzar L. The intrinsic threshold of the fibrinolytic system is modulated by basic carboxypeptidases, but the magnitude of the antifibrinolytic effect of activated thrombin-activable fibrinolysis inhibitor is masked by its instability. J Biol Chem 2004; 279: 27896-904.
33. Ceresa E, Van de Borne K, Peeters M, Lijnen HR, Declerck PJ, Gils A. Generation of a stable activated thrombin activable fibrinolysis inhibitor variant. J Biol Chem 2006; 281: 15878-83.
34. Knecht W, Willemse J, Stenhamre H, Andersson M, Berntsson P, Furebring C, Harrysson A, Hager AC, Wissing BM, Hendriks D, Cronet P. Limited mutagenesis increases the stability of human carboxypeptidase U (TAFIa) and demonstrates the importance of CPU stability over proCPU concentration in down-regulating fibrinolysis. FEBS J 2006; 273: 778-92.
35. Lijnen HR, Van Hoef B, Beelen V, Collen D. Characterization of the murine plasma fibrinolytic system. Eur J Biochem 1994; 224: 863-71.